This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lentigen Receives U.S. Orphan Drug Designation For Novel Gene Therapy For Glioblastoma Multiforme

GAITHERSBURG, Md., Feb. 13, 2013 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives.

"We are very pleased that the FDA has granted our brain cancer product orphan drug status," said Tim Ravenscroft CEO of Lentigen Corporation. "The market exclusivity which this designation provides, together with our intellectual property rights, gives us increased impetus to advance the development of this product, enabling us to play our part in improving the lives of patients with glioblastoma."

"LG631-CD34 consists of the patients' adult hematopoietic stem cells genetically modified with a Lentiviral vector expressing a human MGMT gene variant, which is designed to protect the cells from the toxic side-effects of Temodar*, a standard of care treatment for glioblastoma multiforme" said Dr. Boro Dropulic, the Chief Scientific Officer of Lentigen Corporation. "Protection of blood-forming hematopoietic stem cells from the side-effects effects of Temodar would provide immediate benefits to patients. It  potentially enables higher doses and more intensive drug treatment with reduced toxicity, resulting in improved clinical outcomes.

LG631-CD34 is currently being evaluated in a NIH grant-funded Phase I clinical trial ( http://www.clinicaltrials.gov/ct2/show/NCT01269424) at University Hospitals (UH) Case Medical Center under the leadership of  Stanton Gerson, MD, Director of the Seidman Cancer Center at UH Case Medical Center, Director of the National Center for Regenerative Medicine and Case Comprehensive Cancer Center and Asa, Patricia Shiverick - Jane Shiverick (Tripp) Professor of Hematological Oncology at Case Western Reserve University School of Medicine and Andrew Sloan MD, Associate Professor & Vice-Chairman, Department of Neurological Surgery and the Peter D. Cristal Chair of Neurosurgical Oncology at Case Western Reserve University School of Medicine, Director, Brain Tumor and Neuro-Oncology Center, UH Case Medical Center and a member of the Case Comprehensive Cancer Center. 

"Glioma is such an aggressive and challenging cancer," said Dr. Gerson. "When patients are diagnosed with this life threatening disease, they have an average life expectancy of less than 12 months. The medical community needs to find new treatment strategies that can improve clinical outcomes in this devastating disease. I am hopeful that LG631-CD34 can make an important contribution and help us improve the lives of our patients."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs